[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-disease":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,69,81,112,147,171,197,227,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":42,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100053565","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-aoc-1044-also-referred-to-as-delpacibart-zotadirsen-in-participants-with-dmd-with-gene-mutations-amenable-to-exon-44-skipping-100053565",false,"NCT07587242","A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","SAFARI44","Key Inclusion Criteria:\n\n* Ambulatory males with clinical and genetic diagnosis of DMD\n* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping\n* 7 to 16 years of age at time of consent\n* TTR and NSAA assessment completed within the protocol specified parameters at Screening\n* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.\n\nKey Exclusion Criteria:\n\n* Previous treatment cell or gene therapy.\n* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).\n* Lab values outside of the protocol specified range at Screening\n* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:\n* Less than 1 month, for growth hormone and\u002For testosterone\n* Less than 6 months for givinostat","MALE","7 Years","16 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping",[28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Muscular Dystrophies","Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)","Muscular Disorders, Atrophic","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Diseases (NMD)","Nervous System Diseases","Genetic Diseases","X-Linked","Hereditary","Neonatal Disease","Duchene Muscular Dystrophy","Congenital","DMD",[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"AOC","AOC 1044","AOC 1044-CS3","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","SAFARI","SAFARI 44","Avidity","Avidity Biosciences","Exon Skipping Therapy","Avidity Biosciences Inc., A Novartis Company","del-zota","NOT_YET_RECRUITING","2026-07-10",{"date":60,"type":61},"2026-07-13","ACTUAL",{"date":63,"type":22},"2026-06",{"date":65,"type":22},"2030-07",{"name":67,"class":68},"Avidity Biosciences, Inc.","INDUSTRY",{"id":70,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":26,"conditions":73,"keywords":74,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":80,"locationsCount":4},"100638788",{"count":21,"type":22},[25],[28,29,30,31,32,33,34,35,36,37,38,39,40,41],[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"2026-05-08",{"date":77,"type":61},"2026-05-14",{"date":63,"type":22},{"date":65,"type":22},{"name":67,"class":68},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100508123","cerebral-monitoring-using-pulsatile-near-infrared-spectroscopy-in-neonates-100508123","NCT05896306","Cerebral Monitoring Using Pulsatile Near Infrared Spectroscopy in Neonates","Assessment of Cerebral Monitoring Using the Pulsatile Near Infrared Spectroscopy in Neonates Immediately After Birth - a Prospective Observational Pilot Study","pNIRS","Inclusion Criteria:\n\n* Term and preterm neonates observed routinely at the resuscitation desk\n* Decision to conduct full life support\n* Written parental informed consent\n\nExclusion Criteria:\n\n* No decision to conduct full life support\n* No written parental informed consent\n* Congenital malformation","ALL","0 Minutes","15 Minutes",{"count":93,"type":22},40,"OBSERVATIONAL","The transition from fetus to newborn is a complex physiological process. Monitoring this process to detect potential disruptions is critical but remains a challenge. Initial evaluation of neonates is usually based on visual inspection, palpation and\u002For auscultation, and response to stimuli. To objectify the condition of the newborn during this vulnerable transitional period, Virginia Apgar developed a clinical assessment-based scoring system called the Apgar Score, which is widely used around the world. However, there is significant inter-observer and intra-observer variability in clinical assessments using the Apgar score. To objectively assess the condition of the newborn, the latest guidelines for postnatal adaptation and resuscitation recommend the use of electrocardiography (ECG) and pulse oximetry in the delivery room in addition to clinical evaluation. These monitoring methods allow non-invasive continuous monitoring of SpO2 (Oxygen saturation) as well as heart rate (HR), but do not provide information about potentially compromised cardiovascular status, resulting in severely restricted oxygen transport to tissues.\n\nCerebral Oxygenation:\n\nThe brain is one of the most vulnerable organs to hypoxia during the postnatal adaptation period. The recommended routine monitoring during the neonatal transition is SpO2 and heart rate. Unfortunately, these parameters do not provide any information about cerebral blood flow or oxygen supply or brain activity. About 30% of premature babies develop cerebral hemorrhage in the first 3 days after birth. This can lead to the development of hydrocephalus, poor neurological outcome and even death. For the above reasons, there is increasing interest in additional brain monitoring. Our research group has already shown in various studies that additional cerebral monitoring using near-infrared spectroscopy (NIRS) is possible in newborns immediately after birth and may be beneficial during this vulnerable phase of life. Furthermore, this add-on monitoring could inform interventions to optimize brain oxygenation, potentially affecting survival with improved short- and long-term neurological outcomes.\n\nBackground:\n\nThe transition from fetus to newborn is a complex physiological process. Monitoring this process to detect potential disruptions is critical but remains a challenge. Initial evaluation of neonates is usually based on visual inspection, palpation and\u002For auscultation, and response to stimuli. To objectify the condition of the newborn during this vulnerable transitional period, Virginia Apgar developed a clinical assessment-based scoring system called the Apgar Score, which is widely used around the world. However, there is significant inter-observer and intra-observer variability in clinical assessments using the Apgar score. To objectively assess the condition of the newborn, the latest guidelines for postnatal adaptation and resuscitation recommend the use of electrocardiography (ECG) and pulse oximetry in the delivery room in addition to clinical evaluation. These monitoring methods allow non-invasive continuous monitoring of SpO2 as well as HR, but do not provide information about potentially compromised cardiovascular status, resulting in severely restricted oxygen transport to tissues.\n\nPulsatile mode of NIRS Recently, Hamamatsu developed new software and implemented it as a pulsatile mode in one of their near-infrared spectroscopy (NIRS) instruments, the NIRO 200 NX. In contrast to the conventional NIRS technique, which measures tissue saturation closer to venous oxygen saturation than arterial oxygen saturation, the pulsatile NIRS technique uses a higher measurement rate of 20 Hertz and can therefore measure cerebral pulse rate (cPR) and cerebral arterial oxygen saturation (SnO2) in small vessels.\n\nUsing the non-invasive pulsatile NIRS technique could be a viable new method to continuously monitor blood flow to the brain during resuscitation. This can be particularly beneficial for critically ill newborns and premature babies.\n\nTo date, no data have been published in neonates using the pulsatile NIRS technique.",[38],[87,98,99],"Neonates","Postnatal transition","RECRUITING","2025-11-18",{"date":103,"type":61},"2025-11-19",{"date":105,"type":61},"2023-05-30",{"date":107,"type":22},"2027-05-31",{"name":109,"class":110},"Medical University of Graz","OTHER",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":89,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":124,"conditions":125,"keywords":130,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100522799","evaluation-of-a-multi-country-medical-oxygen-program-100522799","NCT06087315","Evaluation of a Multi-country Medical Oxygen Program","Realist Evaluation and Learning in a Multi-country Medical OXYgen Program (REAL-MOXY)","REAL-MOXY","Sub-study 1:\n\nResearch Question: What are the baseline pulse oximetry and oxygen practices for children admitted to participating health facilities, and what is the level of institutional readiness for oxygen service delivery? Which facilities, representative of high- and low-performing facilities and different levels of care and facility types, can be selected for additional investigation to understand current functioning of oxygen systems?\n\nSetting and Population: The broader MOXY program baseline cross-sectional assessments involve 9 countries. We have selected 6 MOXY countries for the mixed methods studies outlined in this protocol - Nigeria, Uganda, Liberia, Rwanda, Cambodia and Lao PDR - based on pre-existing research collaborations, and with the aim of representing broadly different geographical contexts.\n\nBaseline assessments are being conducted in all facilities participating in the MOXY program in each of the 6 study countries. From this data set, we will analyse primary and secondary outcomes for wards caring for children \\\u003C15 years (including neonatal wards where relevant).\n\nAnalysis\u002Foutcomes: Primary - proportion of admitted children (\\\u003C15 years, including neonates) screened with pulse oximetry. Secondary - proportion of admitted children with hypoxaemia (\\\u003C15 years, including neonates) treated with oxygen. For Real-Moxy the secondary outcome will inform identification of facilities for inclusion.\n\nSub-study 2:\n\nResearch question: Where and how are patients managed from arrival to admission and discharge (or transfer), and how does oxygen equipment move within and between clinical areas? How do process maps vary for different clinical scenarios representing different patient groups: i) pneumonia with and without hypoxaemia; ii) severe, acute illness syndrome with WHO emergency signs (e.g., shock, multi-trauma, seizures); iii) surgical condition and iv) neonatal illness (inborn and outborn)?\n\nSetting and Population: This will be conducted in 10 health facilities in each of the 6 countries (Nigeria, Uganda, Liberia, Rwanda, Lao PDR, Cambodia), selected to represent high and low functioning facility oxygen systems and include secondary and tertiary health facilities from government and non-governmental sectors (identified in sub-study 1). We will focus on admitted children (\\\u003C15 years, including neonates) with (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness. We have chosen these conditions to represent diagnoses with a high prevalence of hypoxaemia, and to capture the nuances of how pulse oximetry and oxygen practices are adapted (or not adapted) to clinical scenarios (e.g., having a lower threshold to provide oxygen to a patient in shock; or targeting safe oxygen saturations in neonates).\n\nAnalysis\u002Foutcomes: Facility maps of patient and equipment flow.\n\nSub-study 3:\n\nResearch question: What is the sequence of emergency care for an unwell child in the first 4 hours, and how are decisions made - particularly relating to oxygen (when to start, stop, how much, what delivery modality, etc.)? What are the points of delays to appropriate care (including pulse oximetry and oxygen) and at what points in time and location could pulse oximetry and oxygen be used better for emergency care of children?\n\nSetting and Population: facilities are same as sub-study 2). Children (\\\u003C15 years, including neonates) presenting with each of 4 acute illness syndromes: (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness.\n\nAnalysis\u002Foutcomes: Patient journey maps.\n\nSub-study 4:\n\nResearch question: How do healthcare workers use pulse oximetry and oxygen for admitted patients, and how does this change over time and vary between patient groups, facility type, and location? How do practices compare with treatment guidelines and where are the priority areas for improving oxygen care?\n\nPopulation and setting: Facilities are same as sub-studies 2\\&3.\n\nAnalysis\u002Foutcomes: Narrative descriptions of handover, ward rounds, and nursing rounds, with specific emphasis on how pulse oximetry is used, and decision making for oxygen therapy.\n\nSub-study 5: Indepth interviews and focus group discussions Research questions: 5a) How do patients\u002Fcaregivers perceive pulse oximetry and oxygen therapy within their broader care experience? 5b) How do healthcare workers, managers and technicians perceive oxygen therapy and the provision of oxygen-related care within the broader care provision experience?\n\nPopulation:\n\n* Patients and caregivers enrolled in sub-study 3 (patient journey mapping).\n* Healthcare workers (bedside), managers (including clinical and non-clinical managers) and technicians in each health facility. We will select staff with direct responsibility for wards caring for children \\\u003C15 years.\n\nAnalysis\u002Foutcomes: Reflexive thematic analysis of interviews and focus group discussions.","0 Years","15 Years",{"count":123,"type":22},1200,"REAL-MOXY is a set of 5 mixed methods studies designed to understand how oxygen and pulse oximetry are used (or not used) at a facility level, to identify opportunities and barriers for strengthening oxygen systems for beneficiaries, users and managers.",[126,38,127,128,129],"Hypoxemia","Pneumonia","Sepsis","Morality",[131,132,133,134,135,136],"Oxygen systems","Pulse oximetry","Low middle income countries","Global health","Mixed-methods evaluation","Realist evaluation","2025-06-11",{"date":139,"type":61},"2025-06-15",{"date":141,"type":61},"2023-11-27",{"date":143,"type":22},"2027-12",{"name":145,"class":110},"Murdoch Childrens Research Institute",3,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":89,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":111},"100561768","new-procedure-to-reduce-mother-newborn-separation-100561768","NCT06594458","New Procedure to Reduce Mother-newborn Separation","To Reduce the Separation of the Mother-newborn Dyad in the First Day of Life Through the Implementation of a New Procedure in the Delivery Room","Inclusion Criteria:\n\n* Infants born by elective cesarean section, with gestational age ≥34 weeks, weight at birth ≥2000 grams, manifesting mild respiratory distress with need for oxygen at FiO2 ≤30%\n* Signature by both parents of an informed consent\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Need for invasive respiratory assistance\n* Need for resuscitation at birth\n* Criteria for perinatal asphyxiation\n* Fetal pathology\n* Failure by both parents to sign up for informed consent","1 Minute","3 Days",{"count":157,"type":22},142,[159],"NA","The goal of this single-centre interventional study without medication neither device (for procedure) is to limit the separation between mother and newborn by implementing a new procedure for the management of the newborn with respiratory distress in the delivery room.\n\nThe main questions it aims to answer are:\n\n* Is it possible to reduce Neonatal Intensive Care Unit admissions within 24 hours of life by applying this new procedure, thus limiting separation between mother and newborn?\n* Does the implementation of this procedure, reducing mother-newborn separation, improves the rate of exclusive breastfeeding?\n\nNewborns with respiratory distress at birth will be evaluated in the delivery room in a dedicated pre-heated incubator, providing additional oxygen if necessary. In case of improvement they will be reunited with the mother, in case of worsening a thoracic ultrasound will be performed to assess the severity and possible hospitalization in Neonatal Intensive Care Unit",[38],"2024-09-10",{"date":164,"type":61},"2024-09-19",{"date":166,"type":61},"2023-10-25",{"date":168,"type":22},"2027-01-31",{"name":170,"class":110},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":89,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100559861","cardiac-surgery-recovery-in-infants-assessed-using-neoneur-feeding-system-100559861","NCT06569641","Cardiac Surgery Recovery in Infants Assessed Using Neoneur Feeding System","Inclusion Criteria:\n\n* Complex congenital heart disease requiring cardiac surgery during first month of life\n* Gestational age\\>=35 weeks at birth\n\nExclusion Criteria:\n\n* No other major non-cardiac congenital anomalies,\n* No history of major neurologic insult\n* Not listed for a heart transplant,\n* Not intubated for \\>4 weeks post-surgery,\n* Not trisomy 13, 18, and 21\n* No cleft lip\u002Fpalate.","1 Day","50 Days",{"count":180,"type":22},35,[159],"A prospective non-randomized longitudinal design of 30-40 infants from initiation of oral feeding until discharge to track feeding changes as a potential indicator of surgical recovery.",[38,184,185],"Post-Surgical Complication","Cardiac Disease",[187],"Recovery","2024-08-21",{"date":190,"type":61},"2024-08-26",{"date":192,"type":22},"2024-09",{"date":194,"type":22},"2026-09",{"name":196,"class":68},"Neoneur LLC",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":205,"sex":89,"minAge":177,"maxAge":155,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":111},"100558011","phase-3-prevention-of-metabolic-acidosis-in-preterm-neonates-by-replacing-sodium-chloride-with-sodium-acetate-in-parenteral-nutrition-100558011","NCT06545565","Prevention of Metabolic Acidosis in Preterm Neonates by Replacing Sodium Chloride With Sodium Acetate in Parenteral Nutrition","Prevention of Metabolic Acidosis in Preterm Neonates by Replacing Sodium Chloride With Sodium Acetate in Parenteral Nutrition - A Randomized Controlled Trial. (PROTECT Trial)","PROTECT","Inclusion Criteria:\n\n1. Written informed consent obtained by parents\u002Flegal representative (according to local regulations) before the initiation of PN.\n2. All the neonates who were admitted to the NICU of AKUH and received PN during 28 days of their life.\n3. Gestational age \\\u003C 33 weeks\n\nExclusion Criteria:\n\n1. Infants with an inborn error of metabolism\n2. Genetic or congenital condition that affects neurodevelopment or requires multiple surgeries (e.g., congenital viral infection, hydrops, complex congenital heart disease, severe dysmorphic features, etc.)\n3. Severe metabolic alkalosis, in critically ill neonates, is defined as a persistent elevation of the serum pH above 7.45 and it also involves a primary increase in serum bicarbonate (HCO3-) concentration \\> 25mEq\u002FL.\n4. Severe Hypernatremia, in critically ill neonates, is defined as persistently high serum sodium levels \\> 150 mmol\u002FL\n5. Severe liver failure and syndromic infants with multiple congenital abnormalities and severe perinatal asphyxia\n\n   \\-",true,{"count":207,"type":22},200,[25],"The goal of this clinical trial is to learn if the addition of sodium acetate in neonatal PN works to prevent and treat metabolic acidosis and associated comorbidities in preterm neonates. It will also teach about the optimal doses of sodium acetate in PN. The main questions it aims to answer are:\n\nIs the incidence of metabolic acidosis reduced in preterm neonates who received daily Sodium acetate in PN therapy (treatment) during the initial weeks of life compared with individuals who received sodium chloride in PN (standard)? Is the rate of neonatal comorbidities reduced in preterm neonates who received daily Sodium acetate in PN therapy (treatment) during the initial weeks of life compared with individuals who received sodium chloride in PN (standard)? What are the optimal neonatal dosing recommendations\u002Fguidelines of sodium acetate in daily PN, which are required to prevent\u002Ftreat metabolic acidosis in the early life of preterm neonates? Researchers will compare Sodium acetate in PN therapy to sodium chloride in PN to see if Sodium acetate works to prevent and treat metabolic acidosis and associated comorbidities.\n\nIncluded Participants:\n\nAll the neonates were admitted to the NICU of AKUH and received PN during 28 days of their lives.\n\nParticipants will receive sodium acetate or sodium chloride Written informed consent was obtained by parents\u002Flegal representatives (according to local regulations) before the initiation of PN. Gestational age \\\u003C 33 weeks Included in the study before 72 hours of life",[211,38,212],"Metabolic Acidosis","Neonatal Complication",[214,215,216,217],"metabolic acidosis","sodium acetate","neonates","Parenteral Nutrition","2024-08-07",{"date":220,"type":61},"2024-08-09",{"date":222,"type":61},"2024-07-10",{"date":224,"type":22},"2025-05-10",{"name":226,"class":110},"Aga Khan University Hospital, Pakistan",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":205,"sex":89,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":4},"100552552","applied-forces-during-neonatal-intubation-at-different-heights-of-the-resuscitation-table-100552552","NCT06474572","Applied Forces During Neonatal Intubation at Different Heights of the Resuscitation Table","Applied Forces During Neonatal Intubation With Direct and Video Laryngoscopy at Different Heights of the Resuscitation Table: a Randomized Crossover Manikin Study","IntTab","Inclusion Criteria:\n\n* Level III NICU and PICU consultants, and pediatric residents\n\nExclusion Criteria:\n\n* Refusal to participate","25 Years","65 Years",{"count":238,"type":22},32,[159],"The study aims to compare the applied forces during intubation of a newborn manikin with direct and video laryngoscope at different heights of the resuscitation table. Furthermore, the success at the first attempt, the intubation time and participants' opinion on the procedures were investigated.\n\nThis is an unblinded, randomized, controlled, crossover trial on the applied forces during intubation of a newborn manikin with direct and video laryngoscope at different heights of the resuscitation table.",[38,242],"Intubation",[244,242,245,246,247,248],"Neonate","Direct laryngoscopy","Video laryngoscopy","Forces","Simulation","2024-06-19",{"date":251,"type":61},"2024-06-25",{"date":253,"type":22},"2024-06",{"date":253,"type":22},{"name":256,"class":110},"University Hospital Padova",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":89,"minAge":154,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":111},"100552168","neonatologist-performed-lung-ultrasound-nplus-to-guide-respiratory-therapy-to-prevent-extubation-failure-100552168","NCT06469580","Neonatologist-performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy to Prevent Extubation Failure","Neonatologist-performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy to Prevent Extubation Failure in Term and Preterm Neonates- a Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* All preterm and full-term neonates receiving invasive mechanical ventilation at the Division of Neonatology of the Medical University of Graz AND\n* Written informed consent was obtained from parents prior to extubation\n\nExclusion Criteria:\n\nnone","6 Months",{"count":93,"type":22},[159],"The objective of the study is to evaluate the role of neonatologist-performed lung ultrasound (NPLUS) after weaning from invasive mechanical ventilation and extubation. Our aim is to study the diagnostic accuracy of NPLUS and investigate whether LUS leads to earlier actions before clinical deterioration and hence prevents extubation failure.",[38],[270,271,216,272],"neonatologist performed lung ultrasound","extubation failure","consolidation","2024-06-17",{"date":275,"type":61},"2024-06-21",{"date":277,"type":61},"2024-06-01",{"date":279,"type":22},"2025-05",{"name":109,"class":110}]